FR4727M - Hydroxyproline and its drug combinations in the treatment of rheumatic diseases. - Google Patents
Hydroxyproline and its drug combinations in the treatment of rheumatic diseases. Download PDFInfo
- Publication number
- FR4727M FR4727M FR37265A FR37265A FR4727M FR 4727 M FR4727 M FR 4727M FR 37265 A FR37265 A FR 37265A FR 37265 A FR37265 A FR 37265A FR 4727 M FR4727 M FR 4727M
- Authority
- FR
- France
- Prior art keywords
- hydroxyproline
- glucosamine
- treatment
- rheumatic diseases
- drug combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
REPUBLIQUE FRANÇAISEFRENCH REPUBLIC
MINISTERE DE L'INDUSTRIEMINISTRY OF INDUSTRY
SERVICE de la PROPRIÉTÉ INDUSTRIELLEINDUSTRIAL PROPERTY SERVICE
BREVET SPÉCIAL DE MÉDICAMENTSPECIAL MEDICINAL PATENT
P.V. n° 37.265 Classification internationaleP.V. n ° 37.265 International Classification
N° 4.727 M A 61kN ° 4.727 M A 61k
La 1 . hydroxyproline et ses associations médicamenteuses dans 1 etraWëHfôïîfif de s maladies rhumatismales. (Invention : J.-C. Denis et J. Rambaud.) HGINDCV;The 1. hydroxyproline and its drug combinations in the etraWëHfôifif of rheumatic diseases. (Invention: J.-C. Denis and J. Rambaud.) HGINDCV;
14» m h h oh h14 »m h h oh h
! I I I chaoh-c—c—c—c-cho I I I ! oh oh h nh2! I I I chaoh-c — c — c — c-cho I I I! oh oh h nh2
cehiaosn = 179,17cehiaosn = 179.17
La l.hydroxyproline a pour formule :The formula of l.hydroxyproline:
hoho
\\
hc h2chc h2c
-ch2-ch2
II
chch
\n\not
COO-COO-
c5h903n = 131,13c5h903n = 131.13
Propriétés pharmacodynamiques. — Le chlorhydrate de glucosamine et la l.hydroxyproline ont été administrés chez l'animal, respectivement à la dose de 150 et 15 mg/kg, dans les différents tests servant habituellement à mesurer l'action analgésique et l'action anti-inflammatoire des médicaments. Parmi ceux-ci citons notamment le syndrome de torsion provoqué chez la souris par la phényl-benzoquinone, l'inhibition de la douleur provoquée par l'inflammation expérimentale de la patte du rat, l'inflammation provoquée par les pellets de coton ou l'injection d'essence de térébenthine.Pharmacodynamic properties. - Glucosamine hydrochloride and l.hydroxyproline were administered to animals, respectively at a dose of 150 and 15 mg / kg, in the various tests usually used to measure the analgesic action and the anti-inflammatory action of drugs. These include, but are not limited to, torsion syndrome caused in mice by phenyl-benzoquinone, inhibition of pain caused by experimental inflammation of the rat paw, inflammation caused by cotton pellets or turpentine gasoline injection.
Le chlorhydrate de glucosamine et la l.hydroxyproline ont également été administrés à l'animal en association avec les antirhumatismaux connus et notamment :Glucosamine hydrochloride and l.hydroxyproline have also been administered to animals in combination with known anti-rheumatic drugs including:
Acide acétylsalicylique et salicylates;Acetylsalicylic acid and salicylates;
Acétyl p.aminophénol ;Acetyl p.aminophenol;
Phényl - 1 - diméthyl - 2 - 3 - isopyrazolone (antipyrine) ;Phenyl - 1 - dimethyl - 2 - 3 - isopyrazolone (antipyrine);
7 210551 7 •+. prix du fascicule7 210551 7 • +. price of the booklet
Société dite : TECPAN S. A. résidant au Mexique.Company known as: TECPAN S. A. residing in Mexico.
Demandé le 4 novembre 1965, à 15h 3m, à l'aris.Requested on November 4, 1965, at 3 p.m. 3m, at the aris.
Délivré par arrêté du 2 janvier 1967. [Issued by decree of January 2, 1967. [
{Bulletin officiel de la Propriété industrielle [5.5.M.], n° 6 du 6 février 1967.){Official Bulletin of Industrial Property [5.5.M.], No. 6 of February 6, 1967.)
La présente invention consiste en l'utilisation de la l.hydroxyproline en association :The present invention consists of the use of l.hydroxyproline in combination:
- Avec la glucosamine (ou un de ses sels comme chlorhydrate) ;- With glucosamine (or one of its salts as hydrochloride);
Ou avec un médicament antirhumastimal ;Or with an antirhumastimal drug;
Ou avec la glucosamine et un médicament anti-rhumatismal.Or with glucosamine and an anti-rheumatic drug.
La glucosamine a pour formule :Glucosamine has the following formula:
3,5 - dioxo -3.5 - dioxo -
Phényl - 1 - diméthyl^' 2*^"3 '- diméthylamino - 4 pyrazolone (amidopyrine) ;Phenyl - 1 - dimethyl ^ '2 * ^ "3' - 4-dimethylamino-pyrazolone (amidopyrine);
Dioxy - 3,5 diphényl - 1,2 n - butyl - 4 - pyrazo-lidine (phénylbutazone) ;Dioxy - 3,5 diphenyl - 1,2 n - butyl - 4 - pyrazo-lidine (phenylbutazone);
1 - phényl - 2(p.hydroxyphényl)1 - phenyl - 2 (p.hydroxyphenyl)
4 - n - butyl - pyrazolidine ;4 - n - butyl - pyrazolidine;
Griséofulvine ;Griseofulvin;
Hydroxychloroquine ;Hydroxychloroquine ;
Extrait de cartilage articulaire et de moelle osseuse.Extract of articular cartilage and bone marrow.
Les tests pharmacodynamiques ont mis en évidence :Pharmacodynamic tests revealed:
1° L'intérêt d'employer simultanément la glucosamine avec la l.hydroxyproline pour obtenir un , effet anti-inflammatoi're ;1 ° The advantage of simultaneously using glucosamine with l.hydroxyproline to obtain an anti-inflammatory effect;
2° L'intérêt d'adjoindre à la l.hydroxyproline ou à l'association glucosamine - l.hydroxyproline, un médicament antirhumatismal, tel que ceux cités plus haut, si l'on désire obtenir un effet plus rapide et plus important.2 ° The advantage of adding to l.hydroxyproline or to the glucosamine - l.hydroxyproline combination, an antirheumatic drug, such as those mentioned above, if one wishes to obtain a faster and more important effect.
En effet, la l.hydroxyproline et plus encore l'association glucosamine-hydroxyproline non seulement potentialisent les effets des médicaments antirhumatismaux mais aussi prolongent leur action dans le temps et permettent de les employer, pour une même efficacité, à des doses plus faibles et donc moins toxiques.Indeed, l.hydroxyproline and even more the glucosamine-hydroxyproline combination not only potentiate the effects of anti-rheumatic drugs but also prolong their action over time and allow them to be used, for the same effectiveness, at lower doses and therefore less toxic.
Applications thérapeutiques. — La l.hydroxyproline et l'association glucosamine - l.hydroxyproline peuvent être utilisées avec succès dans les différentes affections rhumatismales, soit seules soit simultanément avec les autres médications connues, selon les exemples ci-dessous :Therapeutic applications. - l.hydroxyproline and the glucosamine - l.hydroxyproline combination can be used successfully in various rheumatic conditions, either alone or simultaneously with other known medications, according to the examples below:
Chl. de glucosamine, g 0,200Chl. glucosamine, g 0.200
1. hydroxyproline, g, 0,0201.hydroxyproline, g, 0.020
Excipient q.s. pour un comprimé.Excipient q.s. for one tablet.
4 à 6 comprimés par jour comme fond des affections rhumatismales ;4 to 6 tablets per day as a background for rheumatic affections;
traitement de b. Acétyl p. aminophénol, g 0,400treatment of b. Acetyl p. aminophenol, g 0.400
l.hydroxyproline, g 0,010l. hydroxyproline, g 0.010
2 francs2 francs
[4.727 M][4.727 M]
4 à 6 comprimés par jour, dans les algies rhumatismales ;4 to 6 tablets per day, in rheumatic pain;
c. Acide acétylsalicylique, g 0,250vs. Acetylsalicylic acid, g 0.250
Chl. de glucosamine, g 0,150Chl. glucosamine, g 0.150
1. hydroxyproline, g 0,0151.hydroxyproline, g 0.015
Excipient q.s. pour un comprimé.Excipient q.s. for one tablet.
6 comprimés par jour, dans toutes les algies rhumatismales ;6 tablets per day, for all rheumatic pain;
■d. Dioxy- ,3,5 -diphényl-1,2 -re-butyl-4- 0,100 pyrazolidine, g.■ d. Dioxy-, 3,5 -diphenyl-1,2 -re-butyl-4- 0.100 pyrazolidine, g.
Chl. de glucosamine, g 0,100Chl. glucosamine, g 0.100
1. hydroxyproline, g 0,0101.hydroxyproline, g 0.010
Excipient q.s. pour un comprimé.Excipient q.s. for one tablet.
1 à 2 comprimés par jour dans les cas de rhumatisme articulaire aigu, polyarthrite rhumatoïde, arthrose, périarthrite, phlébite.1 to 2 tablets per day in cases of rheumatic fever, rheumatoid arthritis, arthritis, periarthritis, phlebitis.
Formes pharmaceutiques. — La glucosamine, ou l'un de ses sels comme le chlorhydrate de glucosamine, et la l.hydroxyproline pourront être utilisés :Pharmaceutical forms. - Glucosamine, or one of its salts such as glucosamine hydrochloride, and l.hydroxyproline can be used:
Soit en solution sous une présentation pharma-ceutiquement acceptable comme les ampoules injectables ou buvables, les sirops, les solutions;Either in solution in a pharma-ceutically acceptable presentation such as injectable or drinkable ampoules, syrups, solutions;
Soit à l'état de poudre sous une présentation pharmaceutiquement acceptable qui pourra être celle de comprimés, gélules, sachets, granulés, suppositoires, seuls ou en association avec d'autres médicaments ou composés pharmaceutiquement acceptables.Either in the powder form in a pharmaceutically acceptable presentation which may be that of tablets, capsules, sachets, granules, suppositories, alone or in combination with other drugs or pharmaceutically acceptable compounds.
RÉSUMÉABSTRACT
1° La présente invention a pour objet l'utilisation de la l.hydroxyproline en association avec la glucosamine (ou un de ses sels comme le chlorhydrate), ou avec un médicament antirhumatismal, ou avec la glucosamine et un médicament antirhumatismal, dans le traitement des maladies rhumatismales.1 ° The present invention relates to the use of l.hydroxyproline in combination with glucosamine (or one of its salts such as hydrochloride), or with an antirheumatic drug, or with glucosamine and an antirheumatic drug, in the treatment rheumatic diseases.
2° L'adjonction de la l.hydroxyproline et plus encore de l'association l.hydroxyproline-chl. de glucosamine à un médicament antirhumatismal détermine une activité thérapeutique plus importante, plus durable et moins toxique que celle que l'on aurait obtenue 'avec le produit antirhumatismal administré isolément.2 ° The addition of l.hydroxyproline and even more of the l.hydroxyproline-chl association. of glucosamine to an antirheumatic drug results in greater, longer lasting and less toxic therapeutic activity than that which would have been obtained with the antirheumatic drug administered alone.
Société dite : TECPAN S. A.Company known as: TECPAN S. A.
Par procuration :Vicarious :
BlétryBlétry
AVIS DOCUMENTAIRE SUR LA NOUVEAUTÉDOCUMENTARY NOTICE ON THE NEW FEATURE
Documents susceptibles de porter atteinte à la nouveauté du médicament : néant.Documents likely to affect the novelty of the medicinal product: none.
Documents illustrant l'état de la technique en la matière : néant.Documents illustrating the state of the art in this area: none.
Pour la vente des fascicules, s'adresser à I'Imprimerie Nationale, 27, rue de la Convention, Paris (15e).For the sale of booklets, contact the Imprimerie Nationale, 27, rue de la Convention, Paris (15th).
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR37265A FR4727M (en) | 1965-11-04 | 1965-11-04 | Hydroxyproline and its drug combinations in the treatment of rheumatic diseases. |
BE688490A BE688490A (en) | 1965-11-04 | 1966-10-19 | 1.hydroxyproline and its drug combinations in the treatment of connective tissue diseases. |
NL6615581A NL6615581A (en) | 1965-11-04 | 1966-11-04 | A method of preparing a therapeutic composition for treating connective tissue diseases. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR37265A FR4727M (en) | 1965-11-04 | 1965-11-04 | Hydroxyproline and its drug combinations in the treatment of rheumatic diseases. |
Publications (1)
Publication Number | Publication Date |
---|---|
FR4727M true FR4727M (en) | 1967-02-06 |
Family
ID=8591826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR37265A Expired FR4727M (en) | 1965-11-04 | 1965-11-04 | Hydroxyproline and its drug combinations in the treatment of rheumatic diseases. |
Country Status (3)
Country | Link |
---|---|
BE (1) | BE688490A (en) |
FR (1) | FR4727M (en) |
NL (1) | NL6615581A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0740938A2 (en) * | 1995-05-05 | 1996-11-06 | IPR-Institute for Pharmaceutical Research Riehen AG | Proline and 4-hydroxyproline as therapeutic agents |
EP1356811A1 (en) * | 2001-01-05 | 2003-10-29 | Kyowa Hakko Kogyo Co., Ltd. | Preventives or remedies for arthritis |
-
1965
- 1965-11-04 FR FR37265A patent/FR4727M/en not_active Expired
-
1966
- 1966-10-19 BE BE688490A patent/BE688490A/en not_active IP Right Cessation
- 1966-11-04 NL NL6615581A patent/NL6615581A/en unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0740938A2 (en) * | 1995-05-05 | 1996-11-06 | IPR-Institute for Pharmaceutical Research Riehen AG | Proline and 4-hydroxyproline as therapeutic agents |
EP0740938A3 (en) * | 1995-05-05 | 1997-03-12 | Ipr Inst Pharm Res Riehen Ag | Proline and 4-hydroxyproline as therapeutic agents |
EP1356811A1 (en) * | 2001-01-05 | 2003-10-29 | Kyowa Hakko Kogyo Co., Ltd. | Preventives or remedies for arthritis |
EP1356811A4 (en) * | 2001-01-05 | 2005-08-17 | Kyowa Hakko Kogyo Kk | Preventives or remedies for arthritis |
US7138386B2 (en) | 2001-01-05 | 2006-11-21 | Kyowa Hakko Kogyo Co., Ltd. | Preventives or remedies for arthritis |
Also Published As
Publication number | Publication date |
---|---|
BE688490A (en) | 1967-03-31 |
NL6615581A (en) | 1967-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Carlsson et al. | Inhibition of ethanol-induced excitation in mice and rats by α-methyl-p-tyrosine | |
CA1241604A (en) | Pharmaceutical products providing enhanced analgesia | |
AR028299A1 (en) | A PHARMACEUTICAL COMPOSITION THAT INCLUDES NATEGLINIDA, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETY. | |
DE69931640T2 (en) | USE OF ACETYLCHOLINESTERASIS INHIBITORS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF FUNCTIONAL AND / OR ORGANIC PAIN SYNDROME | |
KR20020025221A (en) | Composition comprising a tramadol material and an anticonvulsant drug | |
MA32056B1 (en) | Stop oral medications that contain paracetamol and ibuprofen | |
PT1992333E (en) | Flurbiprofen and muscle relaxant combinations | |
JPH0465050B2 (en) | ||
JPS59501413A (en) | Improved analgesic and anti-inflammatory compositions containing ibuprofen | |
FR4727M (en) | Hydroxyproline and its drug combinations in the treatment of rheumatic diseases. | |
GB2287404A (en) | Antiinflammatory and analgesic compositions | |
CN100358515C (en) | Treatment of neurodegenerative and cardiovascular disorders | |
JPH01311022A (en) | 3-substituted-2-oxyindole-1-carboxamide for suppressing t-cell function | |
Weinstock | Acetylcholine and cholinesterase | |
CN103384522A (en) | Caffeic acid derivatives and their use in improving neuronal cell viability | |
JPS59205321A (en) | Anthelmintic synergistical novel composition | |
US1716686A (en) | Pharmaceutical | |
JP2752250B2 (en) | Basic therapeutic agent with analgesic and anti-inflammatory action | |
FR1759M (en) | ||
Tsay et al. | Pharmaceutical and Biological Effects of Suramin and Potential of Its Derivatives and Analogues | |
Waldeck | Modification of the caffeine-induced locomotor stimulation by a cholinergic mechanism | |
Alexandr et al. | Osteoarthrosis: possibilities of complex use of the medication Zeel T within the framework of bioregulatory approach | |
FR100F (en) | New drug endowed in particular with antimitotic activity. | |
KR950700063A (en) | Brofaromine as an agent for treating post-traumatic stress | |
Syrova et al. | Experimental study of the antipyretic effect of oxicams and their compositions with caffeine |